Provention Bio, Inc. (Nasdaq: PRVB), a US-based biopharmaceutical company, announced on Thursday that it has named Thierry Chauche as its new chief financial officer effective 1 December 2021.
The company said that Chauche has financial experience and a strong track record of success for more than two decades. He has served as the head of Strategic Financial Planning and Analysis at Alexion Pharmaceuticals. He has served in roles of increasing responsibility at Intercept Pharmaceuticals, Novartis and Rothschild & Cie.
Current CFO Andrew Drechsler will be retiring in December, following a career of nearly 30 years in the financial and life sciences industry, most notably, the past four years at Provention Bio.
Ashleigh Palmer, Provention Bio CEO & co-founder, said, 'On behalf of the board and our entire team, I would like to thank Andy for his foundational and ongoing contributions throughout these past four years as we've built Provention Bio from an idea into a company we believe is poised to change the therapeutic approach to serious autoimmune diseases from disease treatment to disease interception and prevention. Andy's strategic vision, collaborative spirit and deeply personal connection to autoimmune disease has played such a crucial role in bringing us to this point in our corporate evolution. I would also like to welcome Thierry to the Provention Bio team. His extensive commercial and strategic finance experience as well as his leadership skills are the perfect fit as we continue advancing to the next stage of our company's growth.'
Chemomab secures new patents for CM-101 monoclonal antibody
argenx receives FDA priority review for VYVGART Hytrulo in CIDP
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Ono partners with Shattuck Labs for bifunctional fusion proteins
Artax Biopharma doses first subject in AX-158 Phase 2a psoriasis trial
Innovent Biologics announces CFO transition
Bio-Thera Solutions commences dosing in BAT6026 Phase IA/IIB clinical trial
BioSenic expands patent coverage for ATO therapeutic platform
Celltrion USA submits CT-P47 Biologics License Application to FDA
NS Pharma's NS-229 receives European Commission orphan drug designation
Kyverna Therapeutics' KYV-101 granted US FDA fast track designation
InnoCare Pharma receives U.S. FDA clearance for ICP-248 clinical trial